semagacestat Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Semagacestat (LY-450139) was a candidate drug for a causal therapy against Alzheimer's disease. It was originally developed by Eli Lilly and Elan, and clinical trials were conducted by Eli Lilly. Phase III trials included over 3000 patients, but in August 2010, a disappointing interim analysis, in which semagacestat performed worse than the placebo, led to the trials being stopped.   Wikipedia

Chemistry

  • SMILES: CC(C)[C@H](O)C(=O)N[C@@H](C)C(=O)N[C@@H]1C(=O)N(C)CCc2ccccc12
  • InChIKey: PKXWXXPNHIWQHW-RCBQFDQVSA-N
  • Mol. Mass: 361.44
  • ALogP: 0.38
  • ChEMBL Molecule:
    semagacestat  
More Chemistry

Pharmacology

Alternative names

ly411575 | ly 411575 | ly 411,575 | ly-411575 | ly-411,575 | ly411,575 | ly450139 | ly 450139 | ly-450139 | n2-(2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-n1-(5-methyl-6-oxo-6,7-dihydro-5h-dibenzo(b,d)azepin-7-yl)alaninamide | n2-((2s)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl)-n1-((7s)-5-methyl-6-oxo-6,7-dihydro-5h-dibenzo(b,d)azepin-7-yl)-l-alaninamide | semagacestat

Organizations (1)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (1)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Alzheimer Disease (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 5
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue